8-K 1 navb20200214_8k.htm FORM 8-K navb20200214_8k.htm




Washington, D.C. 20549









Date of Report (date of earliest event reported)

February 14, 2020




(Exact name of registrant as specified in its charter)





(State or other jurisdiction


(IRS Employer

of incorporation)

File Number)

Identification No.)


4995 Bradenton Avenue, Suite 240, Dublin, Ohio


(Address of principal executive offices)

(Zip Code)


Registrant's telephone number, including area code

(614) 793-7500




(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.


Emerging growth company ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class


Trading Symbol(s)


Name of Each Exchange on Which Registered

Common Stock




NYSE American





Item 1.01

Entry into a Material Definitive Agreement.


On February 13, 2020, Navidea Biopharmaceuticals, Inc. (the “Company”) executed agreements with two existing investors, including John K. Scott, Jr. (collectively, the “Investors”), to purchase approximately 4.0 million shares of the Company’s common stock, par value $0.001 per share, for aggregate gross proceeds to Navidea of approximately $3.4 million. The securities to be issued to the Investors will represent approximately 16.5% of the Company’s outstanding common stock after such issuance.


In addition, the Company executed a binding term sheet to sell the judgment entered by the Ohio Court of Common Pleas in favor of Navidea in the amount of $4.3 million plus interest (the “Judgment”), for $4.2 million of proceeds to Navidea. The Company has the option, within 45 days of the sale, to repurchase the Judgment for a 10% premium. Such repurchase option may be in the form of the Company’s common stock at a 10% discount to the then-current market price.


Navidea intends to use the net proceeds from these transactions to fund its research and development programs, including continued advancement of its two Phase 2b and Phase 3 clinical trials of Tc99m tilmanocept in patients with rheumatoid arthritis, and for general working capital purposes and other operating expenses.


The securities offered and to be sold by Navidea in the private placement to Mr. Scott have not been registered under the Securities Act of 1933 (the “Securities Act”), as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the “SEC”) or an applicable exemption from registration requirements. Navidea has agreed to file a registration statement with the SEC covering the resale of the shares of common stock to be issued to Mr. Scott.


The shares of common stock being offered and sold to the other existing investor are being issued pursuant to a shelf registration statement previously filed with and declared effective by the SEC. A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website at www.sec.gov.


This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of Navidea's securities. No offer, solicitation or sale will be made in any state or other jurisdiction in which such offering, solicitation or sale would be unlawful.


On February 14, 2020, the Company issued a press release regarding the matters discussed above. A copy of this press release is attached as Exhibit 99.1 hereto and incorporated in this Item 1.01 by reference.


Item 8.01

Other Information.


As previously reported, on August 14, 2018, the Company received a Deficiency Letter from the NYSE American stating that Navidea was not in compliance with certain NYSE American continued listing standards relating to stockholders’ equity. Specifically, Navidea was not in compliance with Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide (the “Guide”), the highest of such standards requiring an issuer to have stockholders’ equity of $6.0 million or more if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years. Navidea was advised by the NYSE American staff that if we failed to regain compliance with the stockholders’ equity standards by February 14, 2020, the NYSE American would commence delisting procedures.


As shown below, our pro forma stockholders’ equity as of December 31, 2019, is approximately $6.0 million, which is the amount required to comply with Sections 1003(a)(i), (ii) and (iii) of the Guide. As a result, we believe that we have regained compliance with Sections 1003(a)(i), (ii) and (iii) of the Guide as of the end of the plan period. Subject to review by the NYSE American, the Company may be deemed back in compliance with the NYSE American’s continued listing standards. 





The following table sets forth (on an unaudited basis) the Company’s stockholders’ equity position as of December 31, 2019, and as adjusted on a pro-forma basis as of February 14, 2020:



December 31,





February 14,



Stockholders’ equity:


Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued or outstanding

  $     $     $  

Common stock; $.001 par value; 300,000,000 shares authorized; 20,204,247 and 24,377,896 shares issued and outstanding at December 31, 2019 and February 14, 2020, respectively

    211,134       4,174       215,308  

Additional paid-in capital

    345,847,676       3,563,326       349,411,002  

Accumulated deficit



    4,050,000       (343,617,249


Total Navidea stockholders' equity



    7,617,500       6,009,061  

Noncontrolling interest

    731,303             731,303  

Total stockholders’ equity

  $ (877,136


  $ 7,617,500     $ 6,740,364  




The pro forma financial information above is provided for informational purposes only, has not been audited by our independent auditors, may be subject to additional changes, adjustments and modifications as part of the audit process, and may not accurately reflect our stockholders’ equity as presented in our audited or reviewed financial statements as of the periods presented and/or as of December 31, 2019 and/or March 31, 2020.


On February 14, 2020, the Company issued a press release regarding the matters discussed above. A copy of this press release is attached as Exhibit 99.2 hereto and incorporated in this Item 8.01 by reference.


Item 9.01

Financial Statements and Exhibits.


(d) Exhibits.





Exhibit Description




Press Release dated February 14, 2020.



Press Release dated February 14, 2020.








Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




Navidea Biopharmaceuticals, Inc.










Date: February 14, 2020


/s/ Jed A. Latkin




Jed A. Latkin

Chief Executive Officer, Chief Operating Officer

and Chief Financial Officer